论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Hou J, Zou K, Yang C, Leng X, Xu Y
Received 31 May 2018
Accepted for publication 29 September 2018
Published 12 November 2018 Volume 2018:11 Pages 8053—8061
DOI https://doi.org/10.2147/OTT.S175855
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Yao Dai
Background: The aim of this
meta-analysis was to assess the clinicopathological and prognostic significance
of circulating tumor cells (CTCs) in patients with esophageal cancer (EC).
Methods: We searched
PubMed, EMBASE, Science Citation Index Expanded, Cochrane library (from
inception to July 2018) with the keywords “esophageal cancer”, “circulating
tumor cells”, “prognosis”, and “peripheral blood”. HR, risk ratio (RR), OR, and
their 95% CIs were set as effect measures. All analyses were performed by STATA
12.0.
Results: Eighteen
studies were retrieved; CTC-positive patients were significantly associated
with poor progression-free survival (PFS) (HR=2.61; 95% CI=2.08–3.28) and
overall survival (OS) (HR=2.50; 95% CI=2.12–2.94). CTC-positive patients were
also associated with high recurrence (OR=2.84; 95% CI=1.81–4.44) and poor
response of chemoradiotherapy (RR=0.64; 95% CI=0.43–0.96). For
clinicopathological characteristics, CTC-positive patients were significantly
associated with TNM staging, depth of infiltration, regional lymph nodes
metastasis, distant metastasis, lymphatic invasion, and venous invasion.
Conclusion: The
meta-analysis has confirmed the significant clinicopathological and prognostic
value of CTC-positive patients for both PFS and OS in patients with EC.
Keywords: esophageal
cancer, CTCs, prognosis, meta-analysis
